Key regions: Brazil, India, Australia, United States, United Kingdom
The demand for Antiviral Drugs in Tajikistan has been increasing steadily over the past few years.
Customer preferences: The customers in Tajikistan have been increasingly aware of the importance of antiviral drugs, especially with the rise of viral infections such as COVID-19. There has been an increase in demand for antiviral drugs that are effective against a wide range of viruses. Customers also prefer drugs that have a lower risk of side effects and are affordable.
Trends in the market: The Antiviral Drugs market in Tajikistan has been growing due to the increasing prevalence of viral infections. The market has seen an increase in the number of antiviral drugs available in the country, with international pharmaceutical companies introducing their products in the market. The market has also witnessed an increase in the number of generic drugs, which has made antiviral drugs more affordable for the customers.
Local special circumstances: Tajikistan has a high burden of infectious diseases, including viral infections such as hepatitis and HIV. The country has a high prevalence of hepatitis C, which has led to an increase in demand for antiviral drugs that are effective against the virus. The government has also been taking steps to improve the healthcare infrastructure in the country, which has led to an increase in the availability of antiviral drugs.
Underlying macroeconomic factors: Tajikistan is a low-income country with a small economy. The healthcare sector in the country is underdeveloped, and there is a shortage of healthcare professionals. The government has been investing in the healthcare sector, but the progress has been slow. The affordability of antiviral drugs is a major concern for the customers in the country, and the government has been taking steps to make healthcare more accessible and affordable. The COVID-19 pandemic has also highlighted the importance of healthcare and has led to an increase in demand for antiviral drugs in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
